CY1112149T1 - Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο - Google Patents
Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργοInfo
- Publication number
- CY1112149T1 CY1112149T1 CY20111101258T CY111101258T CY1112149T1 CY 1112149 T1 CY1112149 T1 CY 1112149T1 CY 20111101258 T CY20111101258 T CY 20111101258T CY 111101258 T CY111101258 T CY 111101258T CY 1112149 T1 CY1112149 T1 CY 1112149T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oils
- surfactant
- fatty
- tasenergy
- antigons
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η συμπερίληψη λιπαρών επίκουρων σε συνθέσεις εμβολίων μπορεί να προκαλέσει δυσκολίες με ορισμένες αντιγονικές συνιστώσες, ιδιαιτέρως με αντιγόνα που περιλαμβάνουν μία συνιστώσα τασιενεργού. Μία μέθοδος για την παρασκευή μίας ανοσογόνου συνθέσεως που περιλαμβάνει ένα αντιγόνο και ένα λιπαρό επίκουρο περιλαμβάνει τον καθαρισμό του αντιγόνου ουσιαστικά απουσία τασιενεργού. Όπου τα τασιενεργά δεν μπορούν να αποφευχθούν, συνδυάζονται τα ακόλουθα: (i) μία αντιγονική συνιστώσα που περιλαμβάνει ένα τασιενεργό και (ii) μία συνιστώσα λιπαρού επίκουρου, για να παρασχεθεί μία σύνθεση στην οποία η κατά βάθος αναλογία του εν λόγω λιπαρού επίκουρου προς το εν τασιενεργό είναι μικρότερη από 1000:1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0515906.6A GB0515906D0 (en) | 2005-08-02 | 2005-08-02 | Mixtures of antigen and adjuvant |
GB0522599A GB0522599D0 (en) | 2005-11-04 | 2005-11-04 | Adjuvants and antigens |
GB0523923A GB0523923D0 (en) | 2005-11-24 | 2005-11-24 | Adjuvants and antigens |
EP06795518A EP1909830B1 (en) | 2005-08-02 | 2006-08-02 | Reducing interference between oil-containing adjuvants and surfactant-containing antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112149T1 true CY1112149T1 (el) | 2015-11-04 |
Family
ID=37684892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111101258T CY1112149T1 (el) | 2005-08-02 | 2011-12-20 | Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο |
Country Status (21)
Country | Link |
---|---|
US (1) | US20090220547A1 (el) |
EP (1) | EP1909830B1 (el) |
JP (1) | JP2009503051A (el) |
KR (1) | KR101321732B1 (el) |
CN (1) | CN103690945A (el) |
AP (1) | AP2745A (el) |
AT (1) | ATE526036T1 (el) |
AU (1) | AU2006274647B2 (el) |
BR (1) | BRPI0614254A2 (el) |
CA (1) | CA2617362A1 (el) |
CY (1) | CY1112149T1 (el) |
DK (1) | DK1909830T3 (el) |
EA (1) | EA014314B1 (el) |
IL (1) | IL189102A (el) |
MX (1) | MX2008001527A (el) |
NO (1) | NO20081033L (el) |
NZ (1) | NZ565512A (el) |
PL (1) | PL1909830T3 (el) |
PT (1) | PT1909830E (el) |
SI (1) | SI1909830T1 (el) |
WO (1) | WO2007015167A2 (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11236366B2 (en) | 2008-08-28 | 2022-02-01 | Novartis Ag | Production of squalene from hyper-producing yeasts |
KR101847848B1 (ko) * | 2011-03-11 | 2018-04-12 | 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 시트룰린을 함유하는 애주번트 조성물 |
FR3002454B1 (fr) * | 2013-02-26 | 2015-04-10 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion |
US9968673B2 (en) | 2013-02-26 | 2018-05-15 | Commissariat á l'ènergie atomique et aux ènergies alternatives | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent |
EP3377114B1 (fr) * | 2015-11-18 | 2020-07-08 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant |
FR3043558B1 (fr) * | 2015-11-18 | 2017-12-29 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3435112A (en) * | 1966-06-21 | 1969-03-25 | Norden Lab Inc | Repository vaccine and method of preparing the same |
US4199565A (en) * | 1979-03-26 | 1980-04-22 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
CA2017507C (en) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
US5718904A (en) * | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US5814321A (en) * | 1995-11-30 | 1998-09-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Oil adjuvant vaccine and method for preparing same |
GB9616351D0 (en) * | 1996-08-02 | 1996-09-11 | Smithkline Beecham Biolog | Vaccine composition |
JP5019494B2 (ja) * | 1997-04-01 | 2012-09-05 | コリクサ コーポレーション | モノホスホリルリピドaの水性免疫アジュバント組成物 |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
KR100586804B1 (ko) * | 1998-07-14 | 2006-06-07 | 와이어쓰 홀딩스 코포레이션 | 모노포스포릴 지질 에이를 함유하는 보조제 및 백신 조성물 |
DE69935606T9 (de) * | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
WO2000062800A2 (en) * | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
PL355287A1 (en) * | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
JP2001151699A (ja) * | 1999-11-29 | 2001-06-05 | Nippon Surfactant Kogyo Kk | 動物用ワクチンのオイルアジュバント |
KR20010105882A (ko) * | 2000-05-19 | 2001-11-29 | 배길훈 | 스티어링 칼럼 구조 |
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
ES2278786T3 (es) * | 2000-09-28 | 2007-08-16 | Novartis Vaccines And Diagnostics, Inc. | Composiciones de microparticulas y procedimientos de fabricacion de las mismas. |
EP1256804B1 (en) * | 2001-05-09 | 2012-09-26 | Bio Merieux | HBcAg expression and diagnostic and therapeutic uses |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
MX2007009961A (es) * | 2005-02-16 | 2008-01-29 | Novartis Vaccines & Diagnostic | Composicion adyuvante que comprende fosfato de aluminio y 3d-mpl. |
WO2006113528A2 (en) * | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
-
2006
- 2006-08-02 EA EA200800509A patent/EA014314B1/ru not_active IP Right Cessation
- 2006-08-02 CA CA002617362A patent/CA2617362A1/en not_active Abandoned
- 2006-08-02 PT PT06795518T patent/PT1909830E/pt unknown
- 2006-08-02 NZ NZ565512A patent/NZ565512A/en not_active IP Right Cessation
- 2006-08-02 WO PCT/IB2006/002581 patent/WO2007015167A2/en active Application Filing
- 2006-08-02 DK DK06795518.7T patent/DK1909830T3/da active
- 2006-08-02 KR KR1020087005183A patent/KR101321732B1/ko not_active IP Right Cessation
- 2006-08-02 CN CN201310726997.4A patent/CN103690945A/zh active Pending
- 2006-08-02 AP AP2008004352A patent/AP2745A/xx active
- 2006-08-02 SI SI200631197T patent/SI1909830T1/sl unknown
- 2006-08-02 AU AU2006274647A patent/AU2006274647B2/en not_active Ceased
- 2006-08-02 EP EP06795518A patent/EP1909830B1/en not_active Revoked
- 2006-08-02 US US11/997,793 patent/US20090220547A1/en not_active Abandoned
- 2006-08-02 MX MX2008001527A patent/MX2008001527A/es active IP Right Grant
- 2006-08-02 AT AT06795518T patent/ATE526036T1/de active
- 2006-08-02 BR BRPI0614254-0A patent/BRPI0614254A2/pt not_active IP Right Cessation
- 2006-08-02 PL PL06795518T patent/PL1909830T3/pl unknown
- 2006-08-02 JP JP2008524624A patent/JP2009503051A/ja active Pending
-
2008
- 2008-01-29 IL IL189102A patent/IL189102A/en not_active IP Right Cessation
- 2008-02-27 NO NO20081033A patent/NO20081033L/no not_active Application Discontinuation
-
2011
- 2011-12-20 CY CY20111101258T patent/CY1112149T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL189102A0 (en) | 2008-08-07 |
EP1909830A2 (en) | 2008-04-16 |
AP2745A (en) | 2013-09-30 |
AU2006274647B2 (en) | 2013-01-10 |
CA2617362A1 (en) | 2007-02-08 |
AU2006274647A1 (en) | 2007-02-08 |
KR20080038384A (ko) | 2008-05-06 |
PT1909830E (pt) | 2011-11-24 |
EA200800509A1 (ru) | 2008-10-30 |
WO2007015167A3 (en) | 2007-05-03 |
WO2007015167A2 (en) | 2007-02-08 |
SI1909830T1 (sl) | 2012-01-31 |
DK1909830T3 (da) | 2011-12-19 |
MX2008001527A (es) | 2008-04-04 |
US20090220547A1 (en) | 2009-09-03 |
EP1909830B1 (en) | 2011-09-28 |
ATE526036T1 (de) | 2011-10-15 |
NO20081033L (no) | 2008-02-27 |
CN103690945A (zh) | 2014-04-02 |
EA014314B1 (ru) | 2010-10-29 |
NZ565512A (en) | 2011-08-26 |
BRPI0614254A2 (pt) | 2011-03-15 |
JP2009503051A (ja) | 2009-01-29 |
KR101321732B1 (ko) | 2013-10-29 |
IL189102A (en) | 2011-09-27 |
PL1909830T3 (pl) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112149T1 (el) | Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο | |
CL2006000880A1 (es) | Composicion inmunogena para causar una respuesta inmunologica contra una especie helicobacter y circovirus porcino que comprende antigenos de dichos patogenos; metodo para inducir una respuesta inmunologica contra dichos patogenos; kit para preparar la composicion inmunogena. | |
CY1118521T1 (el) | Συνθεση εμβολιου και μεθοδος χρησης αυτου | |
MX9306841A (es) | Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos. | |
BRPI0514982A (pt) | adjuvante de glicosilceramida para antìgenos de sacarìdeo | |
CY1120574T1 (el) | Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου | |
NZ596870A (en) | Vaccine compositions comprising a saponin adjuvant | |
AR014762A1 (es) | PROCEDIMIENTO PARA REDUCIR LA INTERFERENCIA DE COMPONENTES POLISACARIDOS CAPSULARES, DE VACUNAS CONJUGADAS DE HAEMOPHILUS INFLUENZAE B (Hib) EN VACUNASDE COMBINACION, VACUNAS DE COMBINACION OBTENIDAS CON DICHO PROCEDIMIENTO DE VACUNACION CONTRA LA DIFTERIA, TETANO, PERTUSSIS Y HAEMOPHILUS INFLUENZAE | |
CY1112572T1 (el) | Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
AR041880A1 (es) | Composicion inmunogena | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
DK1459766T3 (da) | Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner | |
CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
BRPI0520330B8 (pt) | adjuvante a base de ácido polinosínico-policitidílico | |
NO20023829D0 (no) | Proteosom influensavaksine | |
PE20201443A1 (es) | Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma | |
BRPI0621181A8 (pt) | Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico | |
BRPI0007936B8 (pt) | composto, formulação adjuvante imunológica, e formulação de vacina. | |
CU23759A3 (es) | Composiciones inmunogénicas | |
BR112022014830A2 (pt) | Formulações de vacina para coronavírus | |
AR114627A1 (es) | Composición inmunogénica | |
BRPI0113155C1 (pt) | métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b | |
BRPI0608430A2 (pt) | composição adjuvante, processo para preparar a mesma e uso da mesma |